GlassScriptPhysician profile
Jason A Tate
NPI 1336150291
$10,055.93
in general payments reported to CMS, 2019-2025
45 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $1,053 · 2021: $1,889 · 2022: $1,510 · 2023: $1,678 · 2024: $1,179 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,408 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,407.73 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,624.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $974.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $972.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.52 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $559.47 | 2020-2025 | |
| Gilead Sciences, INC. | $488.82 | 2019-2025 | Descovy, Biktarvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.39 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $389.79 | 2019-2024 | Trintellix |
| Abbvie INC. | $311.84 | 2021-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $306.20 | 2022-2025 | |
| Horizon Therapeutics Plc | $290.35 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $248.70 | 2022 | |
| Amgen INC. | $240.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $221.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $217.10 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.